Trials / Completed
CompletedNCT00355641
Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome
A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the safety and tolerability of ropinirole XR in the long-term treatment (up to 52 weeks)of adults with RLS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ropinirole Extended Release (XR) | Dose range of Ropinirole XR of 0.5mg to 6.0mg daily |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-07-24
- Last updated
- 2016-10-28
Locations
65 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00355641. Inclusion in this directory is not an endorsement.